Department of Medical Physics, Research Center of Medical Physics, Mashhad University of Medical Sciences, Mashhad, Iran.
Photodiagnosis Photodyn Ther. 2013 Feb;10(1):72-8. doi: 10.1016/j.pdpdt.2012.06.001. Epub 2012 Jul 1.
This study evaluated the effects of mitoxantrone (MX) as a sensitizer following combined treatment with ionizing radiation and photodynamic therapy in the MCF-7 human breast cancer cell line. Cells were incubated with MX at different concentrations for 90min and exposed to different fluence rates of non-coherent light and different dose rates of ionizing X-ray radiation in independent treatment groups. Additionally, the combined effects of chemotherapy, phototherapy, and radiotherapy were evaluated. The percent cell survival was investigated using the MTT assay. MX acted as both a photosensitizer and radiosensitizer. Furthermore, the use of 1μM MX in combination with PDT at 10J/Cm(2) and 4Gy of X-ray radiation strongly resulted in the death of cancer cells and reduced the percentage of viable cancer cells to 2.4±1.15. Our data demonstrated that the adverse effects of MX in combination with radiotherapy were partially abated, without a reduction in the efficacy of treatment. This new therapeutic avenue for breast cancer therapy merits further investigation using in vivo models for application in humans.
这项研究评估了米托蒽醌（MX）作为增敏剂在联合电离辐射和光动力疗法治疗 MCF-7 人乳腺癌细胞系中的作用。细胞在 MX 不同浓度下孵育 90min，并在独立治疗组中暴露于不同的非相干光通量率和不同剂量率的电离 X 射线辐射下。此外，还评估了化疗、光疗和放疗的联合效应。使用 MTT 法研究细胞存活率。MX 既是光敏剂又是放射增敏剂。此外，使用 1μM MX 联合 PDT 治疗 10J/Cm(2)和 4Gy X 射线辐射强烈导致癌细胞死亡，并将存活癌细胞的百分比降低至 2.4±1.15。我们的数据表明，MX 联合放疗的不良反应部分减轻，而治疗效果没有降低。这种新的乳腺癌治疗方法值得进一步研究，在体内模型中应用于人类。
